Clinical trials are research studies that are designed to determine whether a potential medicine is safe and effective for patients. Patients may participate in ongoing clinical trials of Xencor’s investigational drug candidates if they meet certain enrollment criteria.
Conditions: Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase: Phase 2
Conditions: Metastatic Castration-Resistant Prostate Cancer
Phase: Phase 2
Conditions: B-cell Non-Hodgkin’s Lymphoma; Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Phase: Phase 1
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of plamotamab and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Conditions: Multiple Myeloma
Phase: Phase 1
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
Conditions: Multiple Myeloma
Phase: Phase 1
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
Conditions: Solid Tumors
Phase: Phase 1
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Conditions: Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma; Pancreatic Carcinoma; Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative (TNBC); Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Cancer; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumors
Phase: Phase 1
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb104 in subjects with selected advanced solid tumors.
Conditions: Safety in Healthy Volunteers
Phase: Phase 1
This study will determine the safety and tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of XmAb564 in normal healthy volunteers. XmAb564 is an engineered IL-2 mutein being developed for autoimmune diseases.
Conditions: Clear Cell Renal Cell Carcinoma
Phase: Phase 1
The purpose of this study is to evaluate the safety and tolerability of intravenous (IV) administration of XmAb®819 in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and active dose.
Conditions: Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma; Non-small Cell Lung Cancer, Squamous or Non-squamous; Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Castration-resistant Prostate Cancer; Epithelial Ovarian Cancer; TNBC – Triple-Negative Breast Cancer; Colorectal Cancer
Phase: Phase 1
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Information about Xencor’s clinical trials is available at www.clinicaltrials.gov.